on NANOBIOTIX (EPA:NANO)
New Positive Results for NANOBIOTIX in Phase 1 Melanoma Study
Nanoobiotix presented encouraging Phase 1 results for JNJ-1900 (NBTXR3) in combination with checkpoint inhibitors. This treatment is aimed at patients with anti-PD-1-resistant cutaneous melanoma. Safety data are favorable and efficacy shows promising signals. The recommended dose for Phase 2 is set at 33% of the tumor volume.
A response goal of 47.4% was observed, along with disease control at 78.9%. Median survival is 14.6 months. The investigators believe the approach merits further clinical evaluation. A conference will be held on September 18, 2025, to discuss these results.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NANOBIOTIX news